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Frequency of gene usage and copy number variation within the rear-
ranged Immunoglobin Heavy-Chain Variable locus based on immune
repertoire sequencing. M.J. Rieder1, D. Williamson1, A. Sherwood1, R.
Emerson1, C. Desmarais1, M. Chung1, H. Robins1,2, C. Carlson1,2. 1) Adap-
tive Biotechnologies, Seattle, WA; 2) Fred Hutchinson Cancer Research
Center, Seattle, WA.
The human adaptive immune system is composed of both B and T cells
that undergo somatic recombination at specific loci to create rearrangements
of Variable (V), Diversity (D) and Joining (J) gene segments. For the B-cell
immunoglobin receptor heavy-chain (IGH), the CDR3 regions are defined
by the VDJ gene segments and nucleotide insertions/deletions at these
junctions that create the vast sequence diversity of the IGH repertoire.
Characterizing the germline DNA in these regions is impeded by the high
sequence similarity between gene segments, mutation and copy-number
variation (i.e. large insertions/deletions). Currently, there is a fundamental
lack of information about the baseline IGH immune repertoire V gene usage
and diversity within healthy human controls. To provide an estimate of
this, we sequenced functionally recombined gene segments to infer the
underlying gene structure. From a set of 132 healthy controls we sorted
C19+/CD27+ B-cells from whole blood and amplified genomic DNA using
a highly multiplexed PCR assay that targeted the rearranged IGH receptor
locus. Following DNA sequencing and data processing to assign V, D and
J gene families and names, we examined the usage frequency of IGHV
gene segments across all individuals. We found that of the 98 V gene
segments only 56 (57%) were used at a frequency > 0.1%, and ~10 showed
little to no usage (present in <1% of individuals). This data also allowed us
to identify two IGHV genes currently annotated as orphons (pseudogenes
assigned to an alternate chromosomal location) that had unambiguous func-
tional usage (IGHV4/OR15-8; IGHV3/OR16-09) and therefore must reside
at the IGH locus on chromosome 14. Finally, by taking this functional
approach we were able to screen all V gene segments for germline copy-
number variation (e.g. large insertion/deletion events encompassing individ-
ual genes) by looking for an excess of deletion events or modal changes
in gene usage. We confirmed that existence of 12 of 15 previously identified
deleted IGHV gene segments. Strong deletion evidence was observed for
an additional six IGHV genes (IGHV3-NL1, IGHV3-33, IGHV1-24, IGHV4-
04, IGHV3-41, IGHV3-35) and ten with highly likely germline deletion events.
These data suggest that functional immune profiling of rearranged immune
receptors provides a more robust method of identifying individual structural
variation and provides insight into the immune repertoire of healthy controls.
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Copy Number Variants near SLC2A9 are Associated with Hyperuri-
cemia.R.B. Scharpf1, L. Mireles2, E. Halper-Stromberg3, A. Tin2, A. Chakra-
varti4, E. Boerwinkle5, J. Coresh2, W.H.L. Kao2. 1) Oncology, Johns Hopkins
University School of Medicine, Baltimore, MD; 2) Epidemiology, Johns Hop-
kins School of Public Health, Baltimore, MD; 3) Human Genetics, Johns
Hopkins University School of Medicine, Baltimore, MD; 4) Medicine, Johns
Hopkins University School of Medicine, Baltimore, MD; 5) IMM Center for
Human Genetics, University of Texas School of Public Health, Houston,
Texas.
Hyperuricemia is associated with multiple diseases, including gout, cardio-
vascular disease, and renal disease. Serum urate is highly heritable suggest-
ing a strong genetic component, yet genome-wide association studies of
single nucleotide polymorphisms (SNPs) and serum uric acid concentrations
explain only a small fraction of the heritability. Whether common copy num-
ber variants (CNVs) contribute to uric acid levels is not known. Here, we
use high-throughput genotyping arrays to assess DNA copy number on a
genome-wide scale among 9,738 individuals of European ancestry who
participated in the Atherosclerosis Risk in Communities (ARIC) study. Loss
of DNA copy number at genomic coordinates 10,002,252-10,009,766bp on
chromosome 4p16.1 is associated with a 5.39 percent increase of uric acid
concentrations among women (95% CI: 4.32-6.47, p = 4.4e−24) and a 1.39
percent increase among men (95% CI: 0.30-2.49, p = 0.012). The CNV
locus is approximately 200kb from several SNPs in the urate transporter
SLC2A9 that have been previously associated with uric acid concentrations
in ARIC, including SNP rs7675964. Among women with the same rs7675964
genotype, loss of copy number is associated with a 3.01 percentage increase
(95% CI: 1.96-4.07) of uric acid concentrations (p = 4.84e-33). In addition
to variation of DNA sequence, loss of DNA copy number may contribute to
the genetic predisposition of serum uric acid concentrations, particularly
among women, explaining some of the missing heritability from standard
genome-wide analyses with SNPs.
X : 46025ACH02
09-11-13 02:39:39 Page 40Layout: 30917X : Even
552T
Comprehensive comparison of copy number variations detection
using Illumina Omni 2.5M and Affymetrix CytoScan® arrays. C.
TANG1,2, E.WONG1, H. GUI1, S. CHERNY1,4, P. SHAM1,2,4,5, P. TAM3,5, M.
GARCIA-BARCELÓ3,5. 1) Department of Psychiatry; 2) Centre for Genomic
Sciences; 3) Department of Surgery; 4) State Key Laboratory of Brain and
Cognitive Sciences; 5) Centre for Reproduction, Development and Growth,
the University of Hong Kong, Pokfulam, Hong Kong.
Structural variation has been recognized as a genetic risk factor contribut-
ing to human diseases, and in particular, congenital disorders. Smaller
scale copy number variations (CNVs) have also been linked to a number
of neurodevelopmental phenotypes, including intellectual disability as well
as autism spectrum disorders. The precise detection of CNVs is therefore
necessary for understanding disease pathogenesis. Recently, the new gen-
eration of SNP-based arrays, Affymetrix CytoScan® and Illumina Omni 2.5M
offer an unique opportunity for improved discovery of CNVs with their special
design. We explored the performance of these new platforms by genotyping
in duplicate on each platform, 4 samples from patients diagnosed with a
congenital disease. Performance of the CNV calling was assessed on the
basis of sensitivity and specificity, both within and across platforms using
various CNV detection software. Similar to previous generations of SNP-
based genotyping arrays, the concordance of CNVs was found to be moder-
ate and dependent on the calling software. In general, Cytoscan offered
higher sensitivity whereas more specific calls were achieved using Omni.
To conclude, multiple CNV calling methods should be employed for reliable
CNV calling.
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Characterisation of the RNU2 CNV, a bulky neighbour for BRCA1. C.
Tessereau1, 2, N. Monnet1, M. Imbert1, M. Buisson1, L. Barjhoux1, C.
Cuenin7, C. Schluth-Bolard3, 4, D. Sanlaville3, 4, Z. Herceg7, E. Conseiller2,
M. Ceppi2, L. Duret5, OM. Sinilnikova1, 6, S. Mazoyer1. 1) Genetics of Breast
Cancer, Cancer Research Center of Lyon, CNRS UMR5286/Inserm U1052/
Université Lyon 1, Lyon, France; 2) Genomic Vision, Bagneux, France;
3) Service de Génétique, Laboratoire de Cytogénétique Constitutionnelle,
Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, France;
4) INSERM U1028, CNRS UMR5292, Université Claude Bernard Lyon 1,
Equipe TIGER, 69000 Lyon, France; 5) Laboratoire de Biométrie et Biologie
Evolutive, Université de Lyon, Université Lyon 1, CNRS, INRIA, UMR5558,
Villeurbanne, France; 6) Unité Mixte de Génétique Constitutionnelle des
Cancers Fréquents, Hospices Civils de Lyon, Centre Léon Bérard, Lyon,
France; 7) Epigenetics Team, Molecular Carcinogenesis and Biomarkers
Group, International Agency for Research on Cancer, F-69008, Lyon,
France.
The question of the implication of multiallelic CNVs in complex traits
remains largely open as most of them cannot be genotyped by array technol-
ogy. In this work, we focused on the RNU2 locus, a variable number of
tandem repeats that contains the gene coding for the snRNA U2, an essential
element of the splicing machinery. RNU2 was shown many years ago to
reside close to the breast cancer susceptibility gene BRCA1 but is still
missing from the latest human genome assembly and cannot therefore be
investigated by recent genomic approaches. Using unassembled contigs,
we precisely located RNU2 within the chromosome 17 reference assembly,
124 kb telomeric of BRCA1. By FISH analyses on combed DNA (Molecular
Combing), we determined more precisely the exact allelic number of repeats
than with the previously used Pulse Field Gel Electrophoresis technique
and found a range of 6-82 and a level of heterozygosity of 98% in 41
individuals. We used the 1,000 Genome Project data for analysing the
variability of this macrosatellite by mapping sequence with unlocalized
human genomic contigs and confirmed its high degree of polymorphism
suggesting that depth-of-coverage calculation is a very useful tool for accu-
rate multi-allelic CNV characterization. We found 24 frequent SNPs within
the RNU2 basic unit, and the genotype data for 1,106 individuals confirmed
previous results showing a concerted evolution of this CNV. Thanks to our
precise location, we were able to confirm that the RNU2 array is within the
BRCA1 linkage disequilibrium block, which allowed us to study the RNU2
array transmission over a large number of generations. A surprising resulting
observation is that a highly variable locus can nevertheless be highly stable.
Given the high level of polymorphism of this locus, we also measured the
expression of U2 snRNA by qRT-PCR in 16 individuals carrying 36 to 110
repeats. Although the U2 level varied up to 6.6 times between individuals,
it is not linked to the RNU2 CNV copy number. By pyrosequencing, we
found a higher level of methylation of the RNU2 gene enhancer sequences
in individuals with the highest copy number, suggesting that methylation
could be involved in dosage compensation. These findings extend our knowl-
edge of a recently neglected CNV that could be valuable for evaluating the
potential role of structural variations in disease due to its location next to a
major cancer susceptibility gene.
